Geneva, October 14, 2026 — The first clinical trial of an Ebola vaccine in the Democratic Republic of Congo is expected to begin within weeks, World Health Organization experts said Tuesday, as the country's worst-ever Ebola outbreak passed the 9,000-case mark with deaths exceeding 4,000.
Illustration: health workers in DR Congo battle the country's worst-ever Ebola outbreak, now past 9,000 cases.
What Happened
WHO experts told reporters on Tuesday that the trial — aimed at the Bundibugyo species of Ebola behind the DR Congo outbreak — should start before the end of October, according to MedicalXpress reporting. There are currently no approved vaccines or treatments for this species of the virus.
"We have got strong reassurances that ... it should be starting before the end of this month," said Anthony Scott, chair of the WHO's Strategic Advisory Group of Experts on Immunisation (SAGE).
The trial will test Ervebo, a vaccine already approved against the more common Zaire strain of Ebola, to see whether it offers any cross-protection against Bundibugyo. The group cautioned that early insights suggesting cross-protection might exist are no substitute for evidence from standardized vaccine trials.
Background: A Record Outbreak With No Vaccine
Ebola virus disease spreads through direct contact with the blood or body fluids of infected people and animals, and outbreaks have a high fatality rate. The Zaire species — responsible for the devastating 2014–2016 West Africa epidemic — now has an approved vaccine in Ervebo, which helped contain later flare-ups.
The Bundibugyo species, first identified in Uganda in 2007, is a different story. Though known to science for nearly two decades, it has never had a licensed vaccine or proven treatment, leaving responders in the current DR Congo outbreak with supportive care and infection control as their main tools.
The so-called Tumaini trial in the DRC is designed as a single trial framework that can test the efficacy of multiple vaccines over time. Beyond Ervebo, it is expected to eventually incorporate two Bundibugyo-specific candidate vaccines now moving through earlier-stage, smaller-scale clinical trials: a ChAdOx1 adenoviral vector shot being developed by the University of Oxford, and an mRNA-based candidate from the US-based Moderna group.
Illustration: the upcoming Tumaini trial will test whether the Ervebo vaccine offers cross-protection against the Bundibugyo Ebola species.
Why It Matters
Scale of suffering: With more than 9,000 cases and over 4,000 deaths, this is the largest Ebola outbreak the Democratic Republic of Congo has ever faced — and one of the largest ever recorded anywhere. Each week without a vaccine means more infections that supportive care alone cannot prevent.
A precedent for neglected pathogens: The Bundibugyo gap illustrates a broader pattern in global health: pathogens that mainly threaten lower-income countries often wait years for dedicated vaccines. A successful trial framework here could become a model for testing vaccines against other neglected threats.
Prevention is having a moment: The Ebola news lands in a week of striking reminders that prevention saves lives. A landmark study by the WHO's International Agency for Research on Cancer (IARC), published October 13, found that preventable infections caused about 12% of all new cancer cases worldwide in 2024 — roughly 2.3 million cases, or one in eight. Helicobacter pylori and HPV each accounted for 4% of new diagnoses, hepatitis B for 2%, and Epstein-Barr virus for 1% — most of them preventable through vaccination, treatment, or cure, researchers said.
Systems under strain: Also this week, WHO Director-General Tedros Adhanom Ghebreyesus told health leaders in Cairo that the Eastern Mediterranean region — home to crises in Sudan, Yemen, and the occupied Palestinian territory — remains "the epicentre of global humanitarian need," with more than 117 million people needing assistance even as international health funding falls.
Illustration: the Bundibugyo species behind the DR Congo outbreak has no approved vaccine or treatment.
What Happens Next
If the Tumaini trial launches as expected before the end of October, researchers will begin enrolling participants in outbreak-affected areas — a complex operation requiring cold-chain logistics, community trust, and rigorous safety monitoring in the middle of an active epidemic.
The two Bundibugyo-specific candidates from Oxford and Moderna remain in earlier-phase trials; their path to larger efficacy testing will depend on safety data and manufacturing scale-up. Even in the best case, a licensed Bundibugyo vaccine is likely years away — but a positive cross-protection signal from Ervebo could offer a stopgap tool for this and future outbreaks.
Public health experts will also be watching whether the trial's adaptive design — testing multiple candidates under one framework — speeds up what has historically been a slow, fragmented vaccine pipeline for neglected diseases.
Sponsored: explore today's featured sponsored offers
Frequently Asked Questions
What is the Bundibugyo species of Ebola?
One of several species of Ebola virus, first identified in Uganda's Bundibugyo district in 2007. It causes the same severe hemorrhagic illness as other Ebola species but has never had an approved vaccine or specific treatment.
How is Ervebo different from what is being tested?
Ervebo is already licensed against the Zaire species of Ebola. The new trial will test whether it also protects against Bundibugyo — so-called cross-protection — which is not yet proven.
How does Ebola spread?
Through direct contact with the blood, body fluids, or tissues of infected people or animals. It does not spread through the air like influenza or COVID-19. Safe burial practices and isolation of patients are critical control measures.
What are the symptoms of Ebola?
Fever, severe headache, muscle pain, vomiting, diarrhea, and in severe cases unexplained bleeding. Symptoms typically appear 2 to 21 days after exposure. Early supportive care significantly improves survival chances.
Why did it take so long to get a Bundibugyo vaccine trial?
Vaccine development follows outbreaks and funding. With no licensed product and limited commercial incentive, Bundibugyo candidates advanced slowly until the scale of the current DR Congo outbreak created urgent demand.
Sources
- MedicalXpress — "DR Congo Ebola vaccine trial to begin within weeks: WHO" (October 14, 2026)
- WHO International Agency for Research on Cancer (IARC) — global study on infection-attributable cancers, published October 13, 2026 (via WSNext summary)
- UN News — "WHO calls for urgent health action across the Eastern Mediterranean" (October 14, 2026)
Keywords: DR Congo Ebola outbreak 2026, Ebola vaccine trial, Bundibugyo Ebola species, Tumaini trial, Ervebo cross-protection, WHO SAGE Ebola, Ebola cases deaths Congo, Oxford ChAdOx1 Ebola vaccine, Moderna mRNA Ebola, infection-caused cancer IARC study, preventable cancers HPV H pylori.
Comments
Post a Comment